Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Net Cash Flow (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Net Cash Flow for 16 consecutive years, with $11.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 400.19% to $11.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.0 million, a 223.05% increase, with the full-year FY2024 number at -$8.5 million, up 10.89% from a year prior.
  • Net Cash Flow was $11.1 million for Q3 2025 at Plus Therapeutics, up from -$7.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $11.1 million in Q3 2025 to a low of -$7.6 million in Q2 2025.
  • A 5-year average of $60125.0 and a median of -$1.5 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 498.5% in 2021, then plummeted 3423.42% in 2024.
  • Plus Therapeutics' Net Cash Flow stood at $6.1 million in 2021, then crashed by 135.17% to -$2.1 million in 2022, then dropped by 14.26% to -$2.5 million in 2023, then skyrocketed by 51.35% to -$1.2 million in 2024, then soared by 1028.25% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Net Cash Flow are $11.1 million (Q3 2025), -$7.6 million (Q2 2025), and $9.8 million (Q1 2025).